ライフサイエンスコーパス: primary sclerosing cholangitis

1 erformed for potentially recurrent diseases (primary sclerosing cholangitis).

2 f gallstones, primary biliary cirrhosis, and primary sclerosing cholangitis.

3 ed cholangitis and the steroid-nonresponsive primary sclerosing cholangitis.

4 distinct from UC that is not associated with primary sclerosing cholangitis.

5 aximum of 38.5% observed among patients with primary sclerosing cholangitis.

6 e antigen haplotypes are not associated with primary sclerosing cholangitis.

7 e, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis.

8 ne hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.

9 of pregnancy, primary biliary cirrhosis and primary sclerosing cholangitis.

10 infection does not appear to directly cause primary sclerosing cholangitis.

11 ences have been detected in liver tissues in primary sclerosing cholangitis.

12 of pregnancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

13 the only established long-term treatment for primary sclerosing cholangitis.

14 he median age was 49, and 88% had underlying primary sclerosing cholangitis.

15 isease onset or immediately in patients with primary sclerosing cholangitis.

16 asia in patients with ulcerative colitis and primary sclerosing cholangitis.

17 patients with inflammatory bowel disease and primary sclerosing cholangitis.

18 There were 7 patients with primary sclerosing cholangitis.

19 ed side effects to severe disorders, such as primary sclerosing cholangitis.

20 n treating human cholangiopathies, including primary sclerosing cholangitis.

21 wide association studies as risk factors for primary sclerosing cholangitis.

22 essive familial intrahepatic cholestasis and primary sclerosing cholangitis.

23 ation of MC mediators may be therapeutic for primary sclerosing cholangitis.

24 o benefit both primary biliary cirrhosis and primary sclerosing cholangitis.

25 he severity of primary biliary cirrhosis and primary sclerosing cholangitis.

26 (17%), primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio

27 4 controls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepat

28 as primary biliary cirrhosis (8.2%; P<0.05), primary sclerosing cholangitis (5.2%; P<0.05) or alcohol

29 ic (4.7% vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancrea

30 atitis and primary biliary cirrhosis (7%) or primary sclerosing cholangitis (6%) and autoimmune chola

31 h malignancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

32 than patients with autoimmune hepatitis and primary sclerosing cholangitis (75% vs. 22%, P = .03) or

33 in the biliary epithelia of 30 patients with primary sclerosing cholangitis (a premalignant disease o

34 n of colitis, extensive colonic involvement, primary sclerosing cholangitis, a family history of colo

35 autoimmune pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct

36 (e.g., primary biliary cirrhosis [PBC], and primary sclerosing cholangitis) account for approximatel

37 ; 95% CI 1.34-2.74), and lower likelihood of primary sclerosing cholangitis (adjusted odds ratio 0.38

38 d on BDs in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease,

39 ver tissues were obtained from patients with primary sclerosing cholangitis, alcoholic liver disease,

40 iation between the autoimmune liver diseases primary sclerosing cholangitis and autoimmune hepatitis

41 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are t

42 tors, were up-regulated by cholangiocytes in primary sclerosing cholangitis and cholangiocarcinoma.

43 rs were also detected in human patients with primary sclerosing cholangitis and hepatobiliary cholang

44 Primary sclerosing cholangitis and immunosuppressive use

45 preneoplastic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocar

46 1.3 +/- 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were inde

47 n particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel di

48 r-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent dia

49 of therapies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholesta

50 th other immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrh

51 uclear YAP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrh

52 ing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to

53 t 8 years (or any duration, if they also had primary sclerosing cholangitis) and no history of advanc

54 trahepatic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of t

55 sis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosi

56 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirr

57 s, recurrent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary bi

58 Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colo

59 the diagnoses of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, he

60 ndromes including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and pro

61 tors for CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepa

62 roid-sensitive biliary strictures resembling primary sclerosing cholangitis but with increased serum

63 re comparable with those in patients without primary sclerosing cholangitis, but there is a higher ra

64 s reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulati

65 C alleles in a large group of patients with primary sclerosing cholangitis by using a recently devel

66 Differentiation of primary sclerosing cholangitis can be challenging becaus

67 nescence may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and

68 duration of ulcerative colitis; duration of primary sclerosing cholangitis; Child-Pugh classificatio

69 and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy

70 and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy

71 isease (including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and

72 y brush samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methyl

73 orming markers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

74 llular carcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, ethanol, and cryptogenic

75 Other data collected included history of primary sclerosing cholangitis, family history of colore

76 Patients with autoimmune hepatitis and primary sclerosing cholangitis had a higher frequency of

77 The natural history of large and small duct primary sclerosing cholangitis has been reviewed.

78 Patients with primary sclerosing cholangitis have a poor prognosis; pr

79 number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreati

80 morphisms associated with protection against primary sclerosing cholangitis have been elucidated.

81 eucocyte antigen haplotype associations with primary sclerosing cholangitis have been investigated.

82 Multiple gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

83 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing cholangitis in 35.7%.

84 e enrolled 105 patients with well-documented primary sclerosing cholangitis in a randomized, double-b

85 Primary sclerosing cholangitis in children can mimic aut

86 ost-effective and accurate way of diagnosing primary sclerosing cholangitis in comparison with endosc

87 re is a higher rate of retransplantation for primary sclerosing cholangitis in most centers.

88 and future research efforts should focus on primary sclerosing cholangitis, in addition to primary b

89 Symptoms of primary sclerosing cholangitis include fatigue, jaundice

90 hepatic morphology observed in patients with primary sclerosing cholangitis-induced end-stage cirrhos

91 sm is associated with ulcerative colitis and primary sclerosing cholangitis, inflammatory diseases wi

92 Primary sclerosing cholangitis-inflammatory bowel diseas

93 diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis

94 Primary sclerosing cholangitis is a chronic cholestatic

95 Primary sclerosing cholangitis is a chronic cholestatic

96 Primary sclerosing cholangitis is a chronic cholestatic

97 Primary sclerosing cholangitis is a chronic cholestatic

98 Primary sclerosing cholangitis is a chronic cholestatic

99 Primary sclerosing cholangitis is a chronic cholestatic

100 Primary sclerosing cholangitis is a chronic immune-media

101 Primary sclerosing cholangitis is a chronic, progressive

102 Primary sclerosing cholangitis is a progressive inflamma

103 The genetic susceptibility to primary sclerosing cholangitis is associated, in part, w

104 Liver histology in primary sclerosing cholangitis is characterized by a por

105 Treatment of primary sclerosing cholangitis is confined to supportive

106 ns indicate that the colitis associated with primary sclerosing cholangitis is pathophysiologically d

107 Primary sclerosing cholangitis is strongly linked to inf

108 Genetic heterogeneity among patients with primary sclerosing cholangitis is supported, and further

109 Primary sclerosing cholangitis is the classic hepatobili

110 The etiopathogenesis of primary sclerosing cholangitis is unknown.

111 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid,

112 meric limit of HLA-encoded susceptibility to primary sclerosing cholangitis lies close to the HLA C l

113 st/killer activation in vitro and in vivo in primary sclerosing cholangitis liver specimens.

114 ucts of PBC livers, compared with normal and primary sclerosing cholangitis livers.

115 malignancy included concomitant diagnosis of primary sclerosing cholangitis, longstanding colitis (>1

116 It is suggested that primary sclerosing cholangitis may have a bacterial caus

117 Primary sclerosing cholangitis may overlap with autoimmu

118 Primary sclerosing cholangitis mice and patients have in

119 but any model to explain the development of primary sclerosing cholangitis must take into account th

120 Sera from patients with PBC (n = 47), primary sclerosing cholangitis (n = 15), and healthy vol

121 immune pancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

122 mined sera from patients with PBC (n = 105), primary sclerosing cholangitis (n = 70), and rheumatoid

123 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed se

124 K for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus

125 is unresectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradioth

126 dvances in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis

127 ecent advancements in the areas of childhood primary sclerosing cholangitis, nonalcoholic fatty liver

128 s, and nine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compa

129 onor first LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (

130 gy (overall P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

131 f hepatitis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

132 ic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not asso

133 iver and human liver samples from control or primary sclerosing cholangitis patients were evaluated f

134 IgG4 has been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indic

135 in large bile ducts from the hilar region of primary sclerosing cholangitis patients.

136 ay improve CCA detection, particularly among primary sclerosing cholangitis patients.

137 Underlying primary sclerosing cholangitis, percutaneous biliary int

138 mains the most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a

139 vidence for low-grade dysplasia, strictures, primary sclerosing cholangitis, post-inflammatory polyps

140 c steatohepatitis (HR, 1.35; P < 0.001), and primary sclerosing cholangitis pre-LT (compared with hep

141 In liver tissues from patients with primary sclerosing cholangitis, primary biliary cholangi

142 ined liver tissue samples from patients with primary sclerosing cholangitis, primary biliary cholangi

143 senger RNA (mRNA) in PBC liver compared with primary sclerosing cholangitis (PSC) (P <.05) or normal

144 The prevalence of primary sclerosing cholangitis (PSC) among patients with

145 tion for primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both v

146 ic fibrosis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterize

147 r (including bile duct epithelium) varies in primary sclerosing cholangitis (PSC) and primary biliary

148 Primary sclerosing cholangitis (PSC) and primary biliary

149 dentified colorectal cancer in patients with primary sclerosing cholangitis (PSC) and ulcerative coli

150 Patients with primary sclerosing cholangitis (PSC) are at an increased

151 Patients with primary sclerosing cholangitis (PSC) are at increased ri

152 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent auto

153 Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

154 (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

155 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver

156 nts with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) at 3 transplantatio

157 improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improv

158 stasis and hepatic histology compatible with primary sclerosing cholangitis (PSC) but normal findings

159 Clinical decisions in primary sclerosing cholangitis (PSC) depend upon underst

160 s to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weightin

161 Recurrence of primary sclerosing cholangitis (PSC) following liver tra

162 Patients with primary sclerosing cholangitis (PSC) have a significantl

163 Approximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulc

164 e cholangiography (MRC) for the diagnosis of primary sclerosing cholangitis (PSC) have described comp

165 tors for developing varices in patients with primary sclerosing cholangitis (PSC) have not been well

166 ient population-level data on the effects of primary sclerosing cholangitis (PSC) in patients with in

167 The epidemiology of primary sclerosing cholangitis (PSC) in the United State

168 Primary sclerosing cholangitis (PSC) is a cholestatic li

169 Primary sclerosing cholangitis (PSC) is a chronic bile d

170 Primary sclerosing cholangitis (PSC) is a chronic choles

171 Primary sclerosing cholangitis (PSC) is a chronic choles

172 Primary sclerosing cholangitis (PSC) is a chronic choles

173 Primary sclerosing cholangitis (PSC) is a chronic choles

174 Primary sclerosing cholangitis (PSC) is a chronic fibroi

175 Primary sclerosing cholangitis (PSC) is a chronic inflam

176 Primary sclerosing cholangitis (PSC) is a chronic inflam

177 Primary sclerosing cholangitis (PSC) is a chronic, fibro

178 Primary sclerosing cholangitis (PSC) is a chronic, idiop

179 Primary sclerosing cholangitis (PSC) is a disease of unk

180 Primary sclerosing cholangitis (PSC) is a heterogeneous

181 Primary sclerosing cholangitis (PSC) is a rare but impor

182 Primary sclerosing cholangitis (PSC) is a rare progressi

183 Primary sclerosing cholangitis (PSC) is a rare, but seri

184 Because primary sclerosing cholangitis (PSC) is a risk factor fo

185 Primary sclerosing cholangitis (PSC) is a severe liver d

186 Primary sclerosing cholangitis (PSC) is an idiopathic, p

187 Primary sclerosing cholangitis (PSC) is an incurable cho

188 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepato

189 Genetic susceptibility to primary sclerosing cholangitis (PSC) is associated with

190 Primary sclerosing cholangitis (PSC) is increasingly dia

191 m; however, with the exception of Notch-3 in primary sclerosing cholangitis (PSC) livers, expression

192 Patients with primary sclerosing cholangitis (PSC) may be at higher ri

193 ion over time may predict colectomy, whereas primary sclerosing cholangitis (PSC) may be protective.

194 Patients with primary sclerosing cholangitis (PSC) may develop and ble

195 fetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and

196 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaire

197 linical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and

198 biliary stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver tran

199 expressed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mic

200 Primary sclerosing cholangitis (PSC) patients pose a par

201 Primary sclerosing cholangitis (PSC) patients suffer fro

202 Primary sclerosing cholangitis (PSC) predisposes individ

203 To summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the

204 The possibility of primary sclerosing cholangitis (PSC) recurrence after li

205 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly unde

206 Primary sclerosing cholangitis (PSC) represents a major

207 nts with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) seen at the Mayo Cl

208 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent IL

209 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent in

210 For patients with primary sclerosing cholangitis (PSC) suffering from bact

211 Primary sclerosing cholangitis (PSC) was present in 31/1

212 ents who underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using

213 ents with primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) who underwent ortho

214 had a history of either IBD (29 patients) or primary sclerosing cholangitis (PSC) without evidence of

215 er specimens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non-A, non-

216 Primary sclerosing cholangitis (PSC), a chronic inflamma

217 The pathogenesis of primary sclerosing cholangitis (PSC), a progressive bili

218 Primary sclerosing cholangitis (PSC), age, history of ch

219 59 subjects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy con

220 er diseases primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic live

221 nt in patients with ulcerative colitis (UC), primary sclerosing cholangitis (PSC), and autoimmune hep

222 er transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and

223 uch as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are frequently ass

224 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

225 f pancreatic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mi

226 pidemiology and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune scleros

227 In primary sclerosing cholangitis (PSC), bile fluid is freq

228 of hepatolithiasis and 20 archival cases of primary sclerosing cholangitis (PSC), both of which are

229 ammatory bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary

230 particularly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time w

231 Primary sclerosing cholangitis (PSC), first described in

232 hich have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanie

233 formance for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when

234 The influence of sex on primary sclerosing cholangitis (PSC), pre and post-liver

235 ncluding primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an im

236 In primary sclerosing cholangitis (PSC), the focus of this

237 cell-mediated biliary injury is a feature of primary sclerosing cholangitis (PSC).

238 gallstone, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

239 mended for management of adult patients with primary sclerosing cholangitis (PSC).

240 logic standard of reference for diagnosis of primary sclerosing cholangitis (PSC).

241 (H2HR), which is increased in patients with primary sclerosing cholangitis (PSC).

242 emiology and disease course in patients with primary sclerosing cholangitis (PSC).

243 but has not been well studied in those with primary sclerosing cholangitis (PSC).

244 of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

245 ncluding primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

246 itis B, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

247 ratify and predict outcomes in patients with primary sclerosing cholangitis (PSC).

248 10) were obtained from patients affected by primary sclerosing cholangitis (PSC).

249 in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC).

250 advanced primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

251 shown to be ineffective in the treatment of primary sclerosing cholangitis (PSC).

252 ix metalloproteinase 3) on susceptibility to primary sclerosing cholangitis (PSC).

253 atory bowel disease differentiated them from primary sclerosing cholangitis (PSC).

254 end-stage primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC).

255 the assessment of survival in patients with primary sclerosing cholangitis (PSC).

256 s with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

257 patients with end-stage liver disease due to primary sclerosing cholangitis (PSC).

258 lantation in the management of patients with primary sclerosing cholangitis (PSC).

259 ated in the serum and liver of patients with primary sclerosing cholangitis (PSC).

260 Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC).

261 ogression of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

262 BDL) rats; however, no information exists in primary sclerosing cholangitis (PSC).

263 une-mediated inflammatory diseases including primary sclerosing cholangitis (PSC).

264 biliary fibrosis in animal models and human primary sclerosing cholangitis (PSC).

265 reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC).

266 e only treatment for patients with end-stage primary sclerosing cholangitis (PSC); however, selection

267 ave been reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear wh

268 skin malignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or

269 for primary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis

270 mplied greater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied g

271 [BA], primary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a compre

272 nd other bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

273 Circulating lymphocytes from patients with primary sclerosing cholangitis showed rolling adhesion o

274 ellular carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deter

275 tivariable modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to est

276 omy FISH, trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were asso

277 d more frequently (P < .05) in patients with primary sclerosing cholangitis than in patients with cir

278 d more frequently (P < .05) in patients with primary sclerosing cholangitis than in the other 472 pat

279 Yet different from patients with primary sclerosing cholangitis, the expression of CCL25

280 orphisms do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellula

281 iver disease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutriti

282 cently demonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies reg

283 ation between inflammatory bowel disease and primary sclerosing cholangitis underscores the need to f

284 In a group of patients with well-defined primary sclerosing cholangitis, ursodiol provided no cli

285 Cirrhosis not related to primary sclerosing cholangitis was associated with both

286 Primary sclerosing cholangitis was associated with intra

287 Primary sclerosing cholangitis was more strongly associa

288 Isolated inflammatory bowel disease without primary sclerosing cholangitis was not associated with a

289 A paucity of research studies on primary sclerosing cholangitis was noted in this review

290 patients with inflammatory bowel disease and primary sclerosing cholangitis was the identification of

291 mary biliary cirrhosis, and 26 patients with primary sclerosing cholangitis were assessed in a unifor

292 For all recipients, female sex and primary sclerosing cholangitis were associated with impr

293 ation of disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

294 patients with end-stage cirrhosis caused by primary sclerosing cholangitis were compared with the fr

295 nce of other inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases wh

296 idiopathic cholangitides, the most common is primary sclerosing cholangitis, which is associated with

297 59 patients with ulcerative colitis and primary sclerosing cholangitis who were undergoing colon

298 is difficult, particularly in patients with primary sclerosing cholangitis, who are at risk of devel

299 ave associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major

300 brush samples from patients with and without primary sclerosing cholangitis with higher levels of sen